"Liraglutide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
| Descriptor ID |
D000069450
|
| MeSH Number(s) |
D06.472.317.469.500.500.500
|
| Concept/Terms |
NN 2211- NN 2211
- 2211, NN
- NN2211
- NN-2211
|
Below are MeSH descriptors whose meaning is more general than "Liraglutide".
Below are MeSH descriptors whose meaning is more specific than "Liraglutide".
This graph shows the total number of publications written about "Liraglutide" by people in this website by year, and whether "Liraglutide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 7 | 7 |
| 2009 | 0 | 13 | 13 |
| 2010 | 0 | 13 | 13 |
| 2011 | 0 | 18 | 18 |
| 2012 | 0 | 40 | 40 |
| 2013 | 1 | 26 | 27 |
| 2014 | 9 | 48 | 57 |
| 2015 | 50 | 18 | 68 |
| 2016 | 73 | 20 | 93 |
| 2017 | 63 | 17 | 80 |
| 2018 | 57 | 17 | 74 |
| 2019 | 22 | 6 | 28 |
To return to the timeline, click here.
Below are the most recent publications written about "Liraglutide" by people in Profiles.
-
Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy. Br J Clin Pharmacol. 2019 11; 85(11):2512-2523.
-
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care. 2019 10; 42(10):1912-1920.
-
Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies. Diabetes Obes Metab. 2019 11; 21(11):2459-2464.
-
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. Cell Rep. 2019 08 06; 28(6):1447-1454.e4.
-
Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. Drug Des Devel Ther. 2019; 13:2745-2757.
-
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. Diabetes Care. 2019 09; 42(9):1733-1741.
-
Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. Diabetes Obes Metab. 2019 11; 21(11):2450-2458.
-
IDegLira: combining efficacy, durability, and convenience? Lancet Diabetes Endocrinol. 2019 08; 7(8):584-585.
-
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):596-605.
-
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 07 06; 394(10192):39-50.